Mostrar el registro sencillo del ítem
| dc.contributor.author | de-la-Morena-Barrio, María-Eugenia | |
| dc.contributor.author | Corral, Javier | |
| dc.contributor.author | López-García, Cecilia | |
| dc.contributor.author | Jiménez-Díaz, Víctor-Alfonso | |
| dc.contributor.author | Miñano, Antonia | |
| dc.contributor.author | Juan-Salvadores, Pablo | |
| dc.contributor.author | Esteve-Pastor, María-Asunción | |
| dc.contributor.author | Baz-Alonso, José-Antonio | |
| dc.contributor.author | Rubio, Ana-María | |
| dc.contributor.author | Sarabia-Tirado, Francisco | |
| dc.contributor.author | García-Navarro, Miguel | |
| dc.contributor.author | García-Lara, Juan | |
| dc.contributor.author | Marín, Francisco | |
| dc.contributor.author | Marín, Francisco | |
| dc.contributor.author | Vicente, Vicente | |
| dc.contributor.author | Pinar-Bermúdez, Eduardo | |
| dc.contributor.author | Pinar-Bermúdez, Eduardo | |
| dc.contributor.author | Cánovas-López, Sergio-J | |
| dc.contributor.author | de-la-Morena-Valenzuela, Gonzalo | |
| dc.date.accessioned | 2025-11-21T08:44:13Z | |
| dc.date.available | 2025-11-21T08:44:13Z | |
| dc.date.issued | 2022-07 | |
| dc.identifier.citation | De La Morena-Barrio ME, Corral J, López-García C, Jiménez-Díaz VA, Miñano A, Juan-Salvadores P, et al. Contact pathway in surgical and transcatheter aortic valve replacement. Front Cardiovasc Med. 22 de julio de 2022;9:887664. | |
| dc.identifier.issn | 2297-055X | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/21939 | |
| dc.description.abstract | BACKGROUND: Aortic valve replacement is the gold standard treatment for severe symptomatic aortic stenosis, but thrombosis of bioprosthetic valves (PVT) remains a concern. OBJECTIVE: To analyze the factors involved in the contact pathway during aortic valve replacement and to assess their impact on the development of thromboembolic complications. METHODS: The study was conducted in 232 consecutive patients who underwent: transcatheter aortic valve replacement (TAVR, N = 155), and surgical valve replacement (SAVR, N = 77) (MUVITAVI project). Demographic and clinical data, outcomes including a combined end point (CEP) of thrombotic events, and imaging controls were recruited. Samples were collected 24 h before and 48 h after valve replacement. FXII, FXI and (pre)kallikrein were evaluated by Western Blot and specific ELISA with nanobodies. RESULTS: The CEP of thrombotic events was reached by 19 patients: 13 patients presented systemic embolic events and 6 patients subclinical PVT. Valve replacement did not cause FXII activation or generation of kallikrein. There was a significant reduction of FXI levels associated with the procedure, which was statistically more pronounced in SAVR than in TAVR. Cases with reductions of FXI below 80% of basal values had a lower incidence of embolic events during the procedure than patients in whom FXI increased above 150%: 2.7 vs. 16.7%; p: 0.04. CONCLUSION: TAVR or SAVR did not significantly activate the contact pathway. A significant reduction of FXI, was observed, particularly in SAVR, associated with lower incidence of thrombotic events. These results encourage evaluating the usefulness and safety of FXI-directed antithrombotic treatments in these patients. | |
| dc.language.iso | eng | |
| dc.publisher | FRONTIERS MEDIA SA | |
| dc.rights | Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/es/ | * |
| dc.title | Contact pathway in surgical and transcatheter aortic valve replacement | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 35935621 | |
| dc.relation.publisherversion | https://www.frontiersin.org/articles/10.3389/fcvm.2022.887664/full | |
| dc.identifier.doi | 10.3389/fcvm.2022.887664 | |
| dc.journal.title | Frontiers in Cardiovascular Medicine |